<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113171</article-id><article-id pub-id-type="publisher-id">ACM-41093</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_58115969.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  脾切除术联合伊米苷酶治疗儿童戈谢病一例并文献复习
  A Case of Gaucher Disease in the Children Who Accepts the Treatment of Splenectomy and Imiglucerase and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>步</surname><given-names>晓洁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>艳霞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>健</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>玲珍</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>立荣</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>胜寒</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院儿童医学中心血液儿科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1187</fpage><lpage>1192</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：回顾性分析１例伴骨骼损害、脾脏肿大的戈谢病患儿的临床资料，并查阅、复习相关文献，旨在提高临床医师对戈谢病诊治的认识。方法：回顾性分析青岛大学附属医院血液儿科收治的１例伴骨骼损害、脾脏肿大的戈谢病患儿的临床资料，并查阅相关文献进行总结分析，了解切脾的适应征、评估切脾的风险。结果：行脾切除后，患儿血象较前缓解，骨损害情况未见改善；行酶替代治疗后，血象明显好转，骨损害程度较前减轻，患儿肝脏回缩至正常大小。结论：确诊戈谢病之后，及早进行酶替代治疗是治疗戈谢病的关键，及时的酶替代治疗可避免切脾，未行酶替代治疗的脾功能亢进的患儿行脾切除术后可缓解血象。
    Objective: The clinical data of a case of Gaucher disease with bone damage and splenomegaly were retrospectively analyzed, and relevant literatures were reviewed, in order to improve clinicians' understanding of the diagnosis and treatment of Gaucher disease. Methods: The clinical data of a case of Gaucher disease with bone damage and splenomegaly admitted to the hematology pediatrics of children’s medical center in Affiliated Hospital of Qingdao University were retrospectively analyzed, and the relevant literature was reviewed for summary and analysis, so as to understand the indications of splenectomy and evaluate the risk of splenectomy. Results: After splenectomy, the hemogram of the children was relieved, but the condition of bone was not improved; after accepting the enzyme replacement therapy, the hemogram of the children was obviously improved, the degree of the bone damage was reduced, and the liver retracted to the normal size. Conclusion: After the diagnosis of Gaucher disease, early enzyme replacement therapy is the key to the treatment of Gaucher disease. Timely enzyme replacement therapy can avoid the splenectomy. The hemogram of children with hypersplenism without enzyme replacement therapy can be relieved after splenectomy. 
  
 
</p></abstract><kwd-group><kwd>戈谢病，骨骼损害，脾脏切除术，酶替代治疗, Gaucher Disease</kwd><kwd> Bone Lesion</kwd><kwd> Splenectomy</kwd><kwd> Enzyme Replacement Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：回顾性分析１例伴骨骼损害、脾脏肿大的戈谢病患儿的临床资料，并查阅、复习相关文献，旨在提高临床医师对戈谢病诊治的认识。方法：回顾性分析青岛大学附属医院血液儿科收治的１例伴骨骼损害、脾脏肿大的戈谢病患儿的临床资料，并查阅相关文献进行总结分析，了解切脾的适应征、评估切脾的风险。结果：行脾切除后，患儿血象较前缓解，骨损害情况未见改善；行酶替代治疗后，血象明显好转，骨损害程度较前减轻，患儿肝脏回缩至正常大小。结论：确诊戈谢病之后，及早进行酶替代治疗是治疗戈谢病的关键，及时的酶替代治疗可避免切脾，未行酶替代治疗的脾功能亢进的患儿行脾切除术后可缓解血象。</p></sec><sec id="s2"><title>关键词</title><p>戈谢病，骨骼损害，脾脏切除术，酶替代治疗</p></sec><sec id="s3"><title>A Case of Gaucher Disease in the Children Who Accepts the Treatment of Splenectomy and Imiglucerase and Literature Review</title><p>Xiaojie Bu<sup>1*</sup>, Yanxia Zhao<sup>2#</sup>, Jian Jiang<sup>2</sup>, Lingzhen Wang<sup>2</sup>, Lirong Sun<sup>2</sup>, Shenghan Gao<sup>1</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Hematology Pediatrics of Children’s Medical Center in the Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/54-1572039x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The clinical data of a case of Gaucher disease with bone damage and splenomegaly were retrospectively analyzed, and relevant literatures were reviewed, in order to improve clinicians' understanding of the diagnosis and treatment of Gaucher disease. Methods: The clinical data of a case of Gaucher disease with bone damage and splenomegaly admitted to the hematology pediatrics of children’s medical center in Affiliated Hospital of Qingdao University were retrospectively analyzed, and the relevant literature was reviewed for summary and analysis, so as to understand the indications of splenectomy and evaluate the risk of splenectomy. Results: After splenectomy, the hemogram of the children was relieved, but the condition of bone was not improved; after accepting the enzyme replacement therapy, the hemogram of the children was obviously improved, the degree of the bone damage was reduced, and the liver retracted to the normal size. Conclusion: After the diagnosis of Gaucher disease, early enzyme replacement therapy is the key to the treatment of Gaucher disease. Timely enzyme replacement therapy can avoid the splenectomy. The hemogram of children with hypersplenism without enzyme replacement therapy can be relieved after splenectomy.</p><p>Keywords:Gaucher Disease, Bone Lesion, Splenectomy, Enzyme Replacement Therapy</p><disp-formula id="hanspub.41093-formula34"><graphic xlink:href="//html.hanspub.org/file/54-1572039x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/54-1572039x8_hanspub.png" /> <img src="//html.hanspub.org/file/54-1572039x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>戈谢病是一种常染色体隐性遗传病，是全球范围内最为常见的溶酶体贮积疾病之一 [<xref ref-type="bibr" rid="hanspub.41093-ref1">1</xref>]。该病起病原因是葡萄糖脑苷脂酶基因发生突变，导致溶酶体内葡萄糖脑苷脂酶缺乏，葡萄糖脑苷脂无法被正常水解，在肝脏、脾脏、骨骼、脑组织的巨噬细胞溶酶体中贮积，形成戈谢细胞，戈谢细胞浸润组织器官进而引发肝脏肿大、脾脏肿大、骨骼损害等 [<xref ref-type="bibr" rid="hanspub.41093-ref2">2</xref>]。戈谢病患儿临床罕见，现就于我院诊治的１例戈谢病患儿的临床资料进行分析，并结合文献复习如下，以期提高临床医师对戈谢病的认识。</p></sec><sec id="s6"><title>2. 临床资料</title><p>患儿男，11岁，因“确诊戈谢病6年余，脾切除术后5年余”于2020年10月入住青岛大学附属医院儿童医学中心血液儿科。患儿9年余前出现腹部膨隆，无发热、咳喘，无腹痛、吐泻，家属未予重视。8年余前就诊于济南军区总医院，完善腹部超声检查，结果提示重度脾大；完善骨髓穿刺检查，结果提示骨髓增生活跃，粒系、红系增生活跃，淋巴细胞占11.5%，巨核细胞41个；心电图、胸部X线检查大致正常，未予明确诊断。6年8月余前首次就诊于我院，查体示腹部膨隆，脾脏脾线I线14 cm，II线15.5 cm，III线−1 cm；骨髓穿刺检查可见戈谢细胞，诊断为戈谢病，因经济原因未行治疗。6年1月余前就诊于北京协和医院，行酶学检测，结果提示β葡萄糖脑苷酯酶量低于正常值的30%，结合基因检查，诊断为I型戈谢病。予以口服盐酸氨溴索治疗(1次120 mg，1天3次)，患儿腹部膨隆情况未见明显缓解。5年9月余前行腹部CT检查，结果示肝大，脾大，脾脏下缘达盆腔内骶髂关节下缘，脾内多发斑片状强化减低区，考虑脾梗死(见图1)；血常规检查示三系减少，考虑与脾功能亢进有关；血凝检查示部分凝血活酶时间73.50 sec (正常值：24~42 sec)，APTT比值2.49 R (正常值0.81~1.40 R)，行脾切除术，并口服阿司匹林片抗凝治疗。5年7月余前行股骨磁共振检查，结果示右侧股骨中上段异常信号影，考虑与戈谢病骨髓浸润有关。4年3月余前因“左肩关节疼痛”行肩关节磁共振检查，结果示左肩胛骨骨质内异常信号影，左侧肱骨中上段骨髓水肿，左肩关节周围软组织水肿，考虑与戈谢病骨髓浸润有关。3年8月余前不慎摔倒致右侧桡尺骨骨干骨折行手术治疗，术后行骨骼损害评估，髋关节磁共振检查示右侧髂骨、双侧股骨干、右侧股骨头、骨骺异常信号影，膝关节磁共振检查示右侧股骨远段、胫腓骨上段及髌骨内异常信号影，考虑与戈谢病骨髓浸润有关。2年8月余前行骨密度检查，结果提示患儿存在继发性骨质疏松，予以口服阿法骨化醇软胶囊治疗骨质疏松症。行髋关节增强CT检查，结果提示骨损害情况较前相仿，未见好转(见图2)。2年7月余前行伊米苷酶替代治疗，规律复查消化系统超声，提示肝脏肿大情况好转，后肝脏范围逐渐回缩至正常。1年余前复查髋关节磁共振、肩关节及膝关节CT，提示骨损害情况较前好转。3月前再次复查髋关节磁共振、肩关节及膝关节CT，结果提示骨损害情况较上次检查好转。患儿为足月自然生产，为其母第1胎第1产，父母非近亲结婚，母亲孕期健康，患儿生后身体健康，有一弟弟，5岁，体健。家族无相关疾病病史，无特殊家族遗传病史。目前患儿进行规律的酶替代治疗，左肩关节疼痛症状较前减轻，肝脏无肿大，血常规、肝功、肾功、血凝检查均正常，病情控制良好。</p><p>图1. 脾切除术前腹部CT检查图片</p><p>图2. 酶替代治疗前髋关节CT检查图片</p><p>入院体格检查：体温36.6℃，心率88次/分，呼吸22次/分，血压100/60 mmHg (1 mmHg = 0.133 kPa)。神志清，精神好，浅表淋巴结未触及肿大，口唇无紫绀，咽部无充血，扁桃体无肿大。颈软，气管居中，双侧颈静脉无怒张。胸廓对称、无畸形，双肺呼吸音清，未闻及干湿性啰音，心界正常，各瓣膜听诊区未闻及病理性杂音。腹软，无压痛及反跳痛，左上腹可见一15 cm左右疤痕，肝脏未触及，移动性浊音阴性，双下肢无浮肿。</p><p>辅助检查(括号内为正常值范围)：血常规 + CRP：白细胞计数11.22 &#215; 10<sup>9</sup>/L (3.5 &#215; 10<sup>9</sup>/L~9.5 &#215; 10<sup>9</sup>/L)，中性粒细胞计数6.53 &#215; 10<sup>9</sup>/L (1.8 &#215; 10<sup>9</sup>/L~6.3 &#215; 10<sup>9</sup>/L)，淋巴细胞计数2.92 &#215; 10<sup>9</sup>/L (1.1 &#215; 10<sup>9</sup>/L~3.2 &#215; 10<sup>9</sup>/L)，红细胞计数 4.50 &#215; 10<sup>12</sup>/L (4.3 &#215; 10<sup>12</sup>/L~5.8 &#215; 10<sup>12</sup>/L)，血红蛋白125.00 g/L (130~175 g/L)，血小板计数 581.00 &#215; 10<sup>9</sup>/L (100 &#215; 10<sup>9</sup>/L~300 &#215; 10<sup>9</sup>/L)，C反应蛋白1.01 mg/L (0~5 mg/L)；肝功、肾功、血凝正常。</p><p>入院影像学检查:腹部超声提示肝脏大小正常；髋关节磁共振检查提示右侧股骨头半脱位，双侧股骨形态不规则，股骨下端干骺端膨大，中上段见混杂长T1信号影，骨髓腔压脂像信号增高，股骨异常信号影与戈谢病骨髓浸润有关，较前好转(见图3)。</p><p>图3. 酶替代治疗2年后髋关节磁共振检查图片</p></sec><sec id="s7"><title>3. 讨论</title><p>戈谢病患儿骨损害发生率高 [<xref ref-type="bibr" rid="hanspub.41093-ref3">3</xref>]，其骨骼系统并发症常为首发症状，导致患儿生长发育迟缓 [<xref ref-type="bibr" rid="hanspub.41093-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41093-ref5">5</xref>]，严重影响患儿生存质量 [<xref ref-type="bibr" rid="hanspub.41093-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41093-ref7">7</xref>]。该患儿有左肩关节疼痛症状，经检查发现肩胛骨、股骨、髌骨、胫骨、腓骨均受累及。研究发现30%~80%的儿童、青少年起病的戈谢病患者出现生长发育障碍，且与原发病病情密切相关 [<xref ref-type="bibr" rid="hanspub.41093-ref8">8</xref>]。I型戈谢病患儿最早的骨骼表现之一是骨量减少 [<xref ref-type="bibr" rid="hanspub.41093-ref9">9</xref>]，儿童、青少年和成人戈谢病患者均普遍存在骨密度减低的情况 [<xref ref-type="bibr" rid="hanspub.41093-ref10">10</xref>]，包括腰椎、股骨颈、大转子和桡骨远端，非暴力骨折风险增加5倍以上。严重可发生骨坏死，甚至可发展为无菌性骨髓炎 [<xref ref-type="bibr" rid="hanspub.41093-ref11">11</xref>]。该患儿存在骨质疏松情况，骨折风险大，后因不慎摔倒致右侧桡尺骨骨干骨折，但尚未发生骨坏死。戈谢病患者多以脾脏肿大、伴或不伴肝脏肿大为主要表现，同时多伴有血小板减少、贫血等异常。该患儿以脾脏肿大为主要表现，且伴有血小板减少、贫血等血象异常情况，完善骨髓穿刺、葡萄糖脑苷脂酶、基因等相关检查后确诊为戈谢病。但当缺乏神经系统、骨骼或肺等相关表现，而血小板减少和贫血又被单纯考虑为脾功能亢进所致时，戈谢病易漏诊或误诊。</p><p>有报道指出，78%的脾切除术后病人病情长时间内保持稳定，生活质量得到不同程度改善，提示脾切除不应归于预后不良的因素。且近期有研究表明，针对I型戈谢病病人，在脾未切除时进行酶替代疗法，只有30.4%病人达到血小板、肝脾大小、骨危象治疗目标，而脾切除后进行酶替代疗法的病人中40%实现了上述目标，对脾切除术的观点给予支持 [<xref ref-type="bibr" rid="hanspub.41093-ref12">12</xref>]。脾切除术可作为病人无法接受酶替代治疗且病情进展时的选择 [<xref ref-type="bibr" rid="hanspub.41093-ref13">13</xref>]。该患儿病初未接受酶替代治疗，行脾切除术后，患儿血象较前缓解，病情较前稳定。</p><p>有学说认为部分脾切除术的施行越晚越好，对于脾功能亢进的早期症状无需过多干预。但是需要将引起生长发育受限、生活质量下降的机械压迫因素考虑在内。脾切除可能亦会增加肝纤维化的严重程度 [<xref ref-type="bibr" rid="hanspub.41093-ref14">14</xref>]。当戈谢病诊断明确，患者大于4岁，不合并骨痛和神经系统症状，符合下列条件之一时，可考虑进行脾切除术：酶替代治疗效果不理想；酶替代治疗并非最佳方案；脾功能亢进导致血小板明显且持续降低，反复出现出血；需要进行其它急症手术，而血小板减少不能通过酶替代治疗立即纠正；脾脏过大，压迫下腔静脉、胸腹腔脏器，以至患儿呼吸衰竭、活动明显受限；大面积脾梗死；因各种原因无法进行酶替代治疗，如酶替代治疗费用昂贵；合并其它脾脏病变，如脾脓肿等 [<xref ref-type="bibr" rid="hanspub.41093-ref15">15</xref>]。目前脾切除主要在其他治疗方法无法控制的威胁生命的血小板降低合并出血风险高的患者中施行，其他脾切除的适应证为反复发生脾梗死导致的无法缓解的腹痛、严重限制性肺疾病、下腔静脉综合征、不能耐受酶替代治疗的患者等 [<xref ref-type="bibr" rid="hanspub.41093-ref16">16</xref>]。该患儿血常规检查提示三系减少，血凝异常，患儿存在重度脾大、脾功能亢进、脾梗死的情况，且血小板低，出血风险高，生活质量下降，综合考虑行脾切除术。</p><p>酶替代疗法特异性地补充患者体内缺乏的葡萄糖脑苷脂酶，国内最常用的为伊米苷酶，能够显著缩小患者的肝脾体积，恢复血红蛋白及血小板水平 [<xref ref-type="bibr" rid="hanspub.41093-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.41093-ref18">18</xref>]，为I型戈谢病治疗的标准方法 [<xref ref-type="bibr" rid="hanspub.41093-ref19">19</xref>]。该患儿行酶替代治疗之后，血象明显好转，骨损害程度较前减轻，肝脏回缩至正常大小。在可以进行酶替代治疗的情况下，避免脾切除术应成为重要的治疗目标。脾切除术只有在特殊情况下，由经验丰富的戈谢病治疗医师评估后才可考虑 [<xref ref-type="bibr" rid="hanspub.41093-ref20">20</xref>]。葡萄糖脑苷脂在骨髓、肝脏、肺脏等器官的蓄积速度会在脾切除术后骤增；感染、血栓和瘤形成也是脾切除术后的并发症；全脾切除术后，患者体内血小板水平升高并与肺血管内皮细胞相互作用造成血管重塑，增加了肺动脉高压的风险。脾切除术后，重要的脾脏免疫功能的丧失是导致凶险性感染的主要原因。有研究表明I型戈谢病患者脾切除后易发生胆系结石 [<xref ref-type="bibr" rid="hanspub.41093-ref21">21</xref>]。但是该患儿确诊戈谢病4年1月余后才进行酶替代治疗，病初病情未得到有效控制，出现重度脾大、脾脏梗死、脾功能亢进，脾切除术不可避免。</p></sec><sec id="s8"><title>4. 结论</title><p>总之，酶替代疗法可以显著改善脾脏肿大症状 [<xref ref-type="bibr" rid="hanspub.41093-ref22">22</xref>]，也可改善肝脏肿大症状。临床医师可通过识别戈谢病患者的早期骨骼损害表现、脾肿大症状来筛查、确诊戈谢病；确诊戈谢病之后及早进行酶替代治疗可早期干预戈谢病对儿童生长发育的影响、降低切脾率，是治疗戈谢病的关键 [<xref ref-type="bibr" rid="hanspub.41093-ref23">23</xref>]。脾切除可以有效缓解戈谢病患儿临床症状，减少酶替代治疗剂量，而保留副脾可以减少部分脾切除及全脾切除并发症 [<xref ref-type="bibr" rid="hanspub.41093-ref24">24</xref>]。</p></sec><sec id="s9"><title>同意书</title><p>该病例报道已获得病人家属的知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>步晓洁,赵艳霞,姜 健,王玲珍,孙立荣,高胜寒. 脾切除术联合伊米苷酶治疗儿童戈谢病一例并文献复习A Case of Gaucher Disease in the Children Who Accepts the Treatment of Splenectomy and Imiglucerase and Literature Review[J]. 临床医学进展, 2021, 11(03): 1187-1192. https://doi.org/10.12677/ACM.2021.113171</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41093-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Nalysnyk, L., Rotella, P., Simeone, J.C., Hamed, A. and Weinreb, N. (2017) Gaucher Disease Epidemiology and Natural History: A Comprehensive Review of the Literature. Hematology, 22, 65-73.  
&lt;br&gt;https://doi.org/10.1080/10245332.2016.1240391</mixed-citation></ref><ref id="hanspub.41093-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zion, Y.C., Pappadopulos, E., Wajnrajch, M., et al. (2016) Re-Thinking Fatigue in Gaucher Disease. Orphanet Journal of Rare Diseases, 29, 1-7.</mixed-citation></ref><ref id="hanspub.41093-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. &lt;br&gt;https://doi.org/10.11138/ccmbm/2015.12.2.165</mixed-citation></ref><ref id="hanspub.41093-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Casirati, G., Baldini, M., Ulivieri, F.M., et al. (2018) Skeletal Involvement in Type 1 Gaucher Disease: Not Just Bone Mineral Density. Blood Cells, Molecules, and Diseases, 68, 148-152. &lt;br&gt;https://doi.org/10.1016/j.bcmd.2017.06.003</mixed-citation></ref><ref id="hanspub.41093-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Marcucci, G., Zimran, A., Bembi, B., et al. (2014) Gaucher Disease and Bone Manifestations. Calcified Tissue International, 95, 477-494. &lt;br&gt;https://doi.org/10.1007/s00223-014-9923-y</mixed-citation></ref><ref id="hanspub.41093-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Biegstraaten, M., Cox, T.M., Belmatoug, N., et al. (2016) Management Goals for Type 1 Gaucher Disease: An Expert Consensus Document from the European Working Group on Gaucher Disease. Blood Cells, Molecules, and Diseases, 68, 203-208. &lt;br&gt;https://doi.org/10.1016/j.bcmd.2016.10.008</mixed-citation></ref><ref id="hanspub.41093-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. &lt;br&gt;https://doi.org/10.11138/ccmbm/2015.12.2.165</mixed-citation></ref><ref id="hanspub.41093-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kaluzna, M., Trzeciak, I., Ziemnicka, K., Machaczka, M. and Ruchała, M. (2019) Endocrine and Metabolic Disorders in Patients with Gaucher Disease Type 1: A Review. Orphanet Journal of Rare Diseases, 14, Article No. 275.  
&lt;br&gt;https://doi.org/10.1186/s13023-019-1211-5</mixed-citation></ref><ref id="hanspub.41093-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yang, A.C., Bier, L., Overbey, J.R., et al. (2017) Early Manifestations of Type 1 Gaucher Disease in Presymptomatic Children Diagnosed after Parental Carrier Screening. Genetics in Medicine, 19, 652-658.  
&lt;br&gt;https://doi.org/10.1038/gim.2016.159</mixed-citation></ref><ref id="hanspub.41093-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Giraldo, P., Pérez-López, J., Núňez, R., et al. (2016) Patients with Type 1 Gaucher Disease in Spain: A Cross-Sectional Evaluation of Health Status. Blood Cells, Molecules, and Diseases, 56, 23-30.  
&lt;br&gt;https://doi.org/10.1016/j.bcmd.2015.10.001</mixed-citation></ref><ref id="hanspub.41093-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hughes, D., Mikosch, P., Belmatoug, N., et al. (2019) Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research, 34, 996-1013. &lt;br&gt;https://doi.org/10.1002/jbmr.3734</mixed-citation></ref><ref id="hanspub.41093-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Orenstein, M., Barbouth, D., Bodamer, O.A. and Weinreb, N.J. (2014) Patients with Type 1 Gaucher Disease in South Florida, USA; Demographics, Genotypes, Disease Severity and Treatment Outcomes. Orphanet Journal of Rare Diseases, 9, Article No. 45. &lt;br&gt;https://doi.org/10.1186/1750-1172-9-45</mixed-citation></ref><ref id="hanspub.41093-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张博健, 乔海泉. 戈谢病的外科研究进展[J]. 腹部外科, 2019, 32(2): 144-147.</mixed-citation></ref><ref id="hanspub.41093-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Motta, I., Filocamo, M., Poggiali, E., et al. (2016) A Multicentre Observational Study for Early Diagnosis of Gaucher Disease in Patients with Splenomegaly and/or Thrombocytopenia. European Journal of Haematology, 96, 352-359.  
&lt;br&gt;https://doi.org/10.1111/ejh.12596</mixed-citation></ref><ref id="hanspub.41093-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Essabar L, Meskini T, Lamalmi N, et al. (2015) Gaucher’s Disease: Report of 11 Cases with Review of Literature. Pan Afr Med J., 20, 18. &lt;br&gt;https://doi.org/10.11604/pamj.2015.20.18.4112</mixed-citation></ref><ref id="hanspub.41093-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Van Dussen, L., Biegstraaten, M., Dijkgraaf, M.G.W. and Hollak, C.E.M. (2014) Modelling Gaucher Disease Progression: Long Term Enzyme Replacement Therapy Reduces the Incidence of Splenectomy and Bone Complications. Orphanet Journal of Rare Diseases, 9, Article No. 112. &lt;br&gt;https://doi.org/10.1186/s13023-014-0112-x</mixed-citation></ref><ref id="hanspub.41093-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Revel-Vilk, S., Szer, J., Mehta, A., et al. (2018) How We Manage Gaucher Disease in the Era of Choices. British Journal of Haematology, 182, 467-480. &lt;br&gt;https://doi.org/10.1111/bjh.15402</mixed-citation></ref><ref id="hanspub.41093-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会儿科学分会遗传代谢内分泌学组, 中华医学会儿科学分会血液学组, 中华医学会血液学分会红细胞疾病(贫血)学组. 中国戈谢病诊治专家共识[J]. 中华儿科杂志, 2015, 53(4): 256-261.</mixed-citation></ref><ref id="hanspub.41093-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">El-Beshlawy, A., Tylki-Szymanska, A., Vellodi, A., et al. (2017) Long-Term Hematological, Visceral, and Growth Outcomes in Children with Gaucher Disease Type 3 Treated with Imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Molecular Genetics and Metabolism, 120, 47-56.  
&lt;br&gt;https://doi.org/10.1016/j.ymgme.2016.12.001</mixed-citation></ref><ref id="hanspub.41093-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">中国成人戈谢病诊治专家共识(2020) [J]. 中华医学杂志, 2020, 100(24): 1841-1849.</mixed-citation></ref><ref id="hanspub.41093-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zimmermann, A., Popp, R.A., Al-Khzouz, C., et al. (2016) Cholelithia-sis in Patients with Gaucher Disease Type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. Journal of Gastrointestinal and Liver Diseases, 25, 447-455. &lt;br&gt;https://doi.org/10.15403/jgld.2014.1121.254.zim</mixed-citation></ref><ref id="hanspub.41093-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">韩冰, 陈苗, 杨辰. 戈谢病多学科诊疗专家共识(2020) [J]. 协和医学杂志, 2020, 11(6): 682-697.</mixed-citation></ref><ref id="hanspub.41093-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Clarke, L.A. and Hollak, C.E.M. (2015) The Clinical Spectrum and Pathophysiology of Skeletal Complications in Lysosomal Storage Disorders. Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism, 29, 219-235.  
&lt;br&gt;https://doi.org/10.1016/j.beem.2014.08.010</mixed-citation></ref><ref id="hanspub.41093-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">莫志强, 王大勇, 李小松, 等. 脾切除及保留副脾治疗儿童戈谢病的疗效观察[J]. 中华小儿外科杂志, 2016, 37(7): 537-540.</mixed-citation></ref></ref-list></back></article>